| PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression H Tang, Y Liang, RA Anders, JM Taube, X Qiu, A Mulgaonkar, X Liu, ... The Journal of clinical investigation 128 (2), 580-588, 2018 | 481 | 2018 |
| Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF T Takeshima, LM Pop, A Laine, P Iyengar, ES Vitetta, R Hannan Proceedings of the National Academy of Sciences 113 (40), 11300-11305, 2016 | 161 | 2016 |
| Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial SA Rosenthal, C Hu, O Sartor, LG Gomella, MB Amin, J Purdy, ... Journal of Clinical Oncology 37 (14), 1159, 2019 | 151 | 2019 |
| Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial R Hannan, V Tumati, XJ Xie, LC Cho, BD Kavanagh, J Brindle, D Raben, ... European Journal of Cancer 59, 142-151, 2016 | 150 | 2016 |
| An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors T Wang, R Lu, P Kapur, BS Jaiswal, R Hannan, Z Zhang, I Pedrosa, ... Cancer discovery 8 (9), 1142-1155, 2018 | 149 | 2018 |
| Fully automated organ segmentation in male pelvic CT images A Balagopal, S Kazemifar, D Nguyen, MH Lin, R Hannan, A Owrangi, ... Physics in Medicine & Biology 63 (24), 245015, 2018 | 146 | 2018 |
| A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk … HM Sandler, C Hu, SA Rosenthal, O Sartor, LG Gomella, M Amin, J Purdy, ... Journal of Clinical Oncology 33 (18_suppl), LBA5002-LBA5002, 2015 | 132 | 2015 |
| Segmentation of the prostate and organs at risk in male pelvic CT images using deep learning S Kazemifar, A Balagopal, D Nguyen, S McGuire, R Hannan, S Jiang, ... Biomedical Physics & Engineering Express 4 (5), 055003, 2018 | 124 | 2018 |
| The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis RJM Correa, AV Louie, NG Zaorsky, EJ Lehrer, R Ellis, L Ponsky, I Kaplan, ... European urology focus 5 (6), 958-969, 2019 | 104 | 2019 |
| Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases CJ Wang, A Christie, MH Lin, M Jung, D Weix, L Huelsmann, K Kuhn, ... International Journal of Radiation Oncology* Biology* Physics 98 (1), 91-100, 2017 | 75 | 2017 |
| Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC)(RADVAX RCC). HJ Hammers, D Vonmerveldt, C Ahn, RM Nadal, CG Drake, MR Folkert, ... Journal of Clinical Oncology 38 (6_suppl), 614-614, 2020 | 74 | 2020 |
| Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder M Rouanne, DF Bajorin, R Hannan, MD Galsky, SB Williams, A Necchi, ... European urology oncology 3 (6), 728-738, 2020 | 73 | 2020 |
| Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer Y Zhang, J Schoenhals, A Christie, O Mohamad, C Wang, I Bowman, ... International Journal of Radiation Oncology* Biology* Physics 105 (2), 367-375, 2019 | 70 | 2019 |
| A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases JJ Meyer, RD Foster, N Lev-Cohain, T Yokoo, Y Dong, RE Schwarz, ... Annals of surgical oncology 23, 218-224, 2016 | 66 | 2016 |
| Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment D Ishihara, L Pop, T Takeshima, P Iyengar, R Hannan Cancer Immunology, Immunotherapy 66, 281-298, 2017 | 63 | 2017 |
| PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response J Vento, A Mulgaonkar, L Woolford, K Nham, A Christie, A Bagrodia, ... Journal for immunotherapy of cancer 7, 1-6, 2019 | 59 | 2019 |
| Hypofractionated whole-breast radiation therapy: does breast size matter? R Hannan, RF Thompson, Y Chen, K Bernstein, R Kabarriti, W Skinner, ... International Journal of Radiation Oncology* Biology* Physics 84 (4), 894-901, 2012 | 57 | 2012 |
| Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade C Moore, CC Hsu, WM Chen, BPC Chen, C Han, M Story, T Aguilera, ... International Journal of Radiation Oncology* Biology* Physics 110 (5), 1306-1316, 2021 | 56 | 2021 |
| Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate … R Hannan, H Zhang, A Wallecha, R Singh, L Liu, P Cohen, A Alfieri, ... Cancer Immunology, Immunotherapy 61, 2227-2238, 2012 | 54 | 2012 |
| PNC‐28, a p53‐derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo J Michl, B Scharf, A Schmidt, C Huynh, R Hannan, H Von Gizycki, ... International journal of cancer 119 (7), 1577-1585, 2006 | 51 | 2006 |
